Ogniskowe segmentalne stwardnienie kłębuszków: badanie fazy II leku PRN1008 i SAR441344
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or…